Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial.
Sign Up to like & getrecommendations! Published in 2021 at "Nature medicine"
DOI: 10.1038/s41591-021-01510-7
Abstract: Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-based intralesional oncolytic immunotherapy approved for the treatment of unresectable melanoma. The present, ongoing study aimed to estimate the treatment effect of neoadjuvant T-VEC on recurrence-free… read more here.
Keywords: melanoma; surgery; stage iiib; resectable stage ... See more keywords